Back to top

Promising Developments and Risk-Reward Profile Justify Buy Rating for Pyxis Oncology

Jeffrey La Rosa, an analyst from Leerink Partners, maintained the Buy rating on Pyxis Oncology (PYXS – Research Report). The associated price targe...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Pyxis Oncology, Inc. (PYXS)